Literature DB >> 28798178

Draft Genome Sequence of Mycobacterium avium 11.

Michelle Yee1, David Klinzing2, Jun-Rong Wei3,4, Martin Gengenbacher1,5, Eric J Rubin3,4, Jung-Yien Chien6, Po-Ren Hsueh6,7, Thomas Dick8,5.   

Abstract

Mycobacterium avium accounts for most lung disease caused by nontuberculous mycobacteria (NTM). The lack of effective chemotherapy calls for the discovery of new drugs. Here, we report the draft genome sequence of M. avium 11, a clinical isolate used as a screening strain for NTM-focused drug discovery.
Copyright © 2017 Yee et al.

Entities:  

Year:  2017        PMID: 28798178      PMCID: PMC5552987          DOI: 10.1128/genomeA.00766-17

Source DB:  PubMed          Journal:  Genome Announc


GENOME ANNOUNCEMENT

The slow-growing nontuberculous mycobacterium (NTM) Mycobacterium avium represents a complex (M. avium complex [MAC]) of at least four subspecies. Members of the MAC are opportunistic pathogens ubiquitous in nature. The organisms have been isolated from soil and water samples and infect a diverse range of hosts, including birds, swine, ruminants, and humans (1). MAC pathogens cause the majority of all NTM infections in the United States and other countries, with M. avium subsp. hominissuis being of high clinical significance (1, 2). M. avium subsp. hominissuis can cause lymphadenitis, pulmonary and soft tissue infections, as well as disseminated disease (2, 3). The absence of effective multidrug regimens renders treatment of MAC infections difficult (2). Disseminated infections are commonly observed in patients with AIDS and are very challenging to cure due to adverse drug effects and drug–drug interaction with background HIV therapy (2, 4). Hence, there is an urgent need for new effective drugs with minimal side effects and no drug–drug interaction. Here, we report the draft genome sequence of M. avium 11, which is used as a screening strain in our ongoing NTM-focused drug discovery program (5–7). M. avium 11 was isolated from the bone marrow of an AIDS patient with disseminated MAC infection, including pulmonary infection (National Taiwan University Hospital, Taipei, Taiwan). This clinical isolate forms smooth, opaque, and domed colonies (3) on Middlebrook 7H11 agar after 3 weeks of incubation at 37°C. M. avium 11 is classified as M. avium subsp. hominissuis based on the 3′ region of the hsp65 gene sequence (8) that shows 100% identity when aligned with the hsp65 3′ region of M. avium subsp. hominissuis 104 (GenBank accession no. NC_008595). Genomic DNA of M. avium 11 was extracted from a log-phase liquid culture using the phenol-chloroform method as described previously (9). The DNA libraries were prepared using Covaris shearing and Illumina TruSeq Nano DNA library preparation kits. Two sequencing runs of 2 × 300-bp read lengths were performed using an Illumina MiSeq platform, generating a total of 8,879,671 paired-end reads (AITbiotech, Singapore). These paired-end reads were quality checked using FastQC and subsequently quality trimmed using fqtrim (https://ccb.jhu.edu/software/fqtrim) with a window size of 7, a minimum average Q score of 28, and a minimum posttrim length of 35. The resulting 8,386,266 paired-end reads after trimming were de novo assembled using SPAdes version 3.6.2 (10) (k-mer sizes of 33, 55, 77, 99, and 127), producing 70 contigs with an N50 contig size of 216,071 bp. This assembled draft genome is 5,448,889 bp in size with a GC content of 68.99%. Annotations were performed using the Rapid Annotations using Subsystems Technology (RAST) server version 2 (11) predicted a total of 5,141 coding sequences and 49 RNAs, which includes 46 tRNAs and 3 rRNAs. Interestingly, PHASTER (12) predicted two prophage regions in the genome, including one partial prophage containing 68 coding sequences (65.56% GC content) and one intact prophage containing 56 coding sequences (66.74% GC content).

Accession number(s).

This whole-genome shotgun project has been deposited at DDBJ/ENA/GenBank under the accession number NISH00000000. The version described in this paper is the first version, NISH01000000.
  12 in total

Review 1.  An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases.

Authors:  David E Griffith; Timothy Aksamit; Barbara A Brown-Elliott; Antonino Catanzaro; Charles Daley; Fred Gordin; Steven M Holland; Robert Horsburgh; Gwen Huitt; Michael F Iademarco; Michael Iseman; Kenneth Olivier; Stephen Ruoss; C Fordham von Reyn; Richard J Wallace; Kevin Winthrop
Journal:  Am J Respir Crit Care Med       Date:  2007-02-15       Impact factor: 21.405

2.  Mycobacterium avium complex lung disease therapy.

Authors:  David E Griffith; Kevin L Winthrop
Journal:  Am J Respir Crit Care Med       Date:  2012-09-15       Impact factor: 21.405

3.  Amphiphilic Indole Derivatives as Antimycobacterial Agents: Structure-Activity Relationships and Membrane Targeting Properties.

Authors:  Tianming Yang; Wilfried Moreira; Samuel Agyei Nyantakyi; Huan Chen; Dinah Binte Aziz; Mei-Lin Go; Thomas Dick
Journal:  J Med Chem       Date:  2017-03-28       Impact factor: 7.446

Review 4.  The Mycobacterium avium complex.

Authors:  C B Inderlied; C A Kemper; L E Bermudez
Journal:  Clin Microbiol Rev       Date:  1993-07       Impact factor: 26.132

Review 5.  Genetic diversity and phylogeny of Mycobacterium avium.

Authors:  Laura Rindi; Carlo Garzelli
Journal:  Infect Genet Evol       Date:  2013-12-15       Impact factor: 3.342

6.  Draft Genome Sequence of Mycobacterium abscessus Bamboo.

Authors:  Michelle Yee; David Klinzing; Jun-Rong Wei; Martin Gengenbacher; Eric J Rubin; Thomas Dick
Journal:  Genome Announc       Date:  2017-05-18

7.  Rifabutin Is Active against Mycobacterium abscessus Complex.

Authors:  Dinah Binte Aziz; Jian Liang Low; Mu-Lu Wu; Martin Gengenbacher; Jeanette W P Teo; Véronique Dartois; Thomas Dick
Journal:  Antimicrob Agents Chemother       Date:  2017-05-24       Impact factor: 5.191

8.  The RAST Server: rapid annotations using subsystems technology.

Authors:  Ramy K Aziz; Daniela Bartels; Aaron A Best; Matthew DeJongh; Terrence Disz; Robert A Edwards; Kevin Formsma; Svetlana Gerdes; Elizabeth M Glass; Michael Kubal; Folker Meyer; Gary J Olsen; Robert Olson; Andrei L Osterman; Ross A Overbeek; Leslie K McNeil; Daniel Paarmann; Tobias Paczian; Bruce Parrello; Gordon D Pusch; Claudia Reich; Rick Stevens; Olga Vassieva; Veronika Vonstein; Andreas Wilke; Olga Zagnitko
Journal:  BMC Genomics       Date:  2008-02-08       Impact factor: 3.969

9.  PHASTER: a better, faster version of the PHAST phage search tool.

Authors:  David Arndt; Jason R Grant; Ana Marcu; Tanvir Sajed; Allison Pon; Yongjie Liang; David S Wishart
Journal:  Nucleic Acids Res       Date:  2016-05-03       Impact factor: 16.971

10.  Fragment-Based Whole Cell Screen Delivers Hits against M. tuberculosis and Non-tuberculous Mycobacteria.

Authors:  Wilfried Moreira; Jia Jie Lim; Si Ying Yeo; Pondy M Ramanujulu; Brian W Dymock; Thomas Dick
Journal:  Front Microbiol       Date:  2016-09-07       Impact factor: 5.640

View more
  5 in total

1.  A Rabbit Model to Study Antibiotic Penetration at the Site of Infection for Nontuberculous Mycobacterial Lung Disease: Macrolide Case Study.

Authors:  Firat Kaya; Jacqueline P Ernest; Katherine LoMauro; Martin Gengenbacher; Abdeldjalil Madani; Wassihun Wedajo Aragaw; Matthew D Zimmerman; Jansy P Sarathy; Nadine Alvarez; Isaac Daudelin; Han Wang; Faye Lanni; Danielle M Weiner; Laura E Via; Clifton E Barry; Kenneth N Olivier; Thomas Dick; Brendan K Podell; Radojka M Savic; Véronique Dartois
Journal:  Antimicrob Agents Chemother       Date:  2022-01-31       Impact factor: 5.938

Review 2.  NTM drug discovery: status, gaps and the way forward.

Authors:  Mu-Lu Wu; Dinah B Aziz; Véronique Dartois; Thomas Dick
Journal:  Drug Discov Today       Date:  2018-04-07       Impact factor: 7.851

3.  A Leucyl-tRNA Synthetase Inhibitor with Broad-Spectrum Anti-Mycobacterial Activity.

Authors:  Uday S Ganapathy; Rubén González Del Rio; Mónica Cacho-Izquierdo; Fátima Ortega; Joël Lelièvre; David Barros-Aguirre; Marissa Lindman; Véronique Dartois; Martin Gengenbacher; Thomas Dick
Journal:  Antimicrob Agents Chemother       Date:  2021-02-08       Impact factor: 5.191

4.  Screening of TB Actives for Activity against Nontuberculous Mycobacteria Delivers High Hit Rates.

Authors:  Jian Liang Low; Mu-Lu Wu; Dinah Binte Aziz; Benoît Laleu; Thomas Dick
Journal:  Front Microbiol       Date:  2017-08-15       Impact factor: 5.640

5.  A Mycobacterium tuberculosis NBTI DNA Gyrase Inhibitor Is Active against Mycobacterium abscessus.

Authors:  Uday S Ganapathy; Rubén González Del Río; Mónica Cacho-Izquierdo; Fátima Ortega; Joël Lelièvre; David Barros-Aguirre; Wassihun Wedajo Aragaw; Matthew D Zimmerman; Marissa Lindman; Véronique Dartois; Martin Gengenbacher; Thomas Dick
Journal:  Antimicrob Agents Chemother       Date:  2021-10-04       Impact factor: 5.191

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.